Oncology news

20-04-2016 | Melanoma | Main feed | Article
Editor's pick

KEYNOTE-001 findings add support to pembrolizumab for advanced melanoma

A third of patients with advanced or metastatic melanoma will achieve an objective response to treatment with the programmed cell death protein inhibitor pembrolizumab, suggest KEYNOTE-001 findings, regardless of whether they have previously been treated with ipilimumab.

Source:

JAMA 2016; 315: 1573–1575, 600–1609

27-05-2016 | Oncology | News | Article

Initiatives to improve adolescent, young adult cancer outcomes justified

Analysis of the EUROCARE-5 data shows that although survival for adolescents and young adults with cancer has improved overall, the survival rates for certain malignancies still lag behind those for children.

Source:

Lancet Oncol 2016; Advance online publication

26-05-2016 | Arrhythmia | News | Article

AF linked to increased cancer risk in women

Women with new-onset atrial fibrillation have a significantly increased cancer risk for at least 1 year after AF diagnosis, an analysis of Women’s Health Study data shows.

Source:

JAMA Cardiol 2016; Advance online publication

23-05-2016 | Multiple sclerosis | News | Article

Mitoxantrone for MS linked to colorectal cancer risk

Treatment with mitoxantrone for multiple sclerosis carries only a mildly increased risk of malignancy overall, but the risk of colorectal cancer and leukaemia is heightened, researchers have found.

Source:

Neurology 2016; Advance online publication

18-05-2016 | Chronic myeloid leukaemia | News | Article

Allogeneic HSCT offers good survival for select TKI-refractory CML patients

Allogeneic hematopoietic stem cell transplantation is associated with a high rate of survival for carefully chosen chronic myeloid leukaemia patients who do not respond well to tyrosine kinase inhibitor therapy, research suggests.

Source:

Bone Marrow Transpl 2016; Advance online publication

Triple Chemoimmunotherapy Regimen Offers Best PFS For Advanced CLL

 

Fludarabine, cyclophosphamide and rituximab remains the standard of care for physically fit, treatment-naïve patients with advanced chronic lymphocytic leukaemia

Read the full story on ESMO's oncologyPRO educational website (for registered ESMO members).

approvalsWatch: Oncology

medwireNews@ECC2015

medwireNews@ECC2015

medwireNews brings you coverage of the 2015 European Cancer Congress, held in Vienna, Austria.

Click through to read the full reports of the latest research.

Twitter Icon Follow medwireNews

Click here
image credits